---
document_datetime: 2025-12-02 04:57:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-accord.html
document_name: pregabalin-accord.html
version: success
processing_time: 0.1391205
conversion_datetime: 2025-12-24 04:09:45.729189
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pregabalin Accord

[RSS](/en/individual-human-medicine.xml/66750)

##### Authorised

This medicine is authorised for use in the European Union

pregabalin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pregabalin Accord](#news-on)
- [More information on Pregabalin Accord](#more-information-on-pregabalin-accord-1414)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Pregabalin Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Accord.

For practical information about using Pregabalin Accord, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Pregabalin Accord and what is it used for?

Pregabalin Accord is a medicine used to treat adults with the following conditions:

- neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury;
- epilepsy, where it is used as an 'add-on' to other epilepsy treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain);
- generalised anxiety disorder (long-term anxiety or nervousness about everyday matters).

Pregabalin Accord contains the active substance pregabalin.

Pregabalin Accord is a 'generic medicine'. This means that Pregabalin Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the European Union (EU) called Lyrica.

## How is Pregabalin Accord used?

Pregabalin Accord is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription. The recommended starting dose is 150 mg per day, divided into two or three doses. After one week, the dose can be increased to 300 mg per day. Doses can be increased further until the most effective dose is reached. The maximum dose is 600 mg per day. To stop treatment with Pregabalin Accord, the dose should be reduced gradually, over at least a week. Patients who have kidney problems may need to take lower doses.

## How does Pregabalin Accord work?

The active substance in Pregabalin Accord, pregabalin, is similar in structure to the body's own 'neurotransmitter' gamma?amino butyric acid (GABA), but has very different biological effects. Neurotransmitters are chemicals that allow nerve cells to communicate with each other. The exact way in which pregabalin works is not fully understood, but it is thought to affect the way that calcium enters nerve cells. This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in epilepsy and anxiety.

## How has Pregabalin Accord been studied?

Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Accord.

As for every medicine, the company provided studies on the quality of Pregabalin Accord. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Pregabalin Accord?

Because Pregabalin Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Pregabalin Accord approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Accord has been shown to have comparable quality and to be bioequivalent to Lyrica. Therefore, the CHMP's view was that, as for Lyrica, the benefit outweighs the identified risk. The Committee recommended that Pregabalin Accord be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pregabalin Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Accord have been included in the summary of product characteristics and the package leaflet.

Further information can be found in the [Pregabalin Accord : EPAR - Risk management plan](/en/documents/rmp/pregabalin-accord-epar-risk-management-plan_en.pdf) .

## Other information about Pregabalin Accord

The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Accord on 28 August 2015.

For more information about treatment with Pregabalin Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Pregabalin Accord : EPAR - Summary for the public

Reference Number: EMA/439020/2015

English (EN) (114.31 KB - PDF)

**First published:** 18/09/2015

**Last updated:** 06/07/2017

[View](/en/documents/overview/pregabalin-accord-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-236)

български (BG) (124.29 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/bg/documents/overview/pregabalin-accord-epar-summary-public_bg.pdf)

español (ES) (97.54 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/es/documents/overview/pregabalin-accord-epar-summary-public_es.pdf)

čeština (CS) (122.91 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/cs/documents/overview/pregabalin-accord-epar-summary-public_cs.pdf)

dansk (DA) (142.45 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/da/documents/overview/pregabalin-accord-epar-summary-public_da.pdf)

Deutsch (DE) (98.41 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/de/documents/overview/pregabalin-accord-epar-summary-public_de.pdf)

eesti keel (ET) (96.43 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/et/documents/overview/pregabalin-accord-epar-summary-public_et.pdf)

ελληνικά (EL) (127.39 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/el/documents/overview/pregabalin-accord-epar-summary-public_el.pdf)

français (FR) (97.75 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/fr/documents/overview/pregabalin-accord-epar-summary-public_fr.pdf)

hrvatski (HR) (117.52 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/hr/documents/overview/pregabalin-accord-epar-summary-public_hr.pdf)

italiano (IT) (96.99 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/it/documents/overview/pregabalin-accord-epar-summary-public_it.pdf)

latviešu valoda (LV) (119.36 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/lv/documents/overview/pregabalin-accord-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (120.91 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/lt/documents/overview/pregabalin-accord-epar-summary-public_lt.pdf)

magyar (HU) (117.29 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/hu/documents/overview/pregabalin-accord-epar-summary-public_hu.pdf)

Malti (MT) (361.28 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/mt/documents/overview/pregabalin-accord-epar-summary-public_mt.pdf)

Nederlands (NL) (97.29 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/nl/documents/overview/pregabalin-accord-epar-summary-public_nl.pdf)

polski (PL) (169.53 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/pl/documents/overview/pregabalin-accord-epar-summary-public_pl.pdf)

português (PT) (97.35 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/pt/documents/overview/pregabalin-accord-epar-summary-public_pt.pdf)

română (RO) (118.85 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/ro/documents/overview/pregabalin-accord-epar-summary-public_ro.pdf)

slovenčina (SK) (122.91 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/sk/documents/overview/pregabalin-accord-epar-summary-public_sk.pdf)

slovenščina (SL) (117.41 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/sl/documents/overview/pregabalin-accord-epar-summary-public_sl.pdf)

Suomi (FI) (142.44 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/fi/documents/overview/pregabalin-accord-epar-summary-public_fi.pdf)

svenska (SV) (96.95 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

06/07/2017

[View](/sv/documents/overview/pregabalin-accord-epar-summary-public_sv.pdf)

Pregabalin Accord : EPAR - Risk management plan

English (EN) (211.24 KB - PDF)

**First published:** 18/09/2015

**Last updated:** 27/01/2025

[View](/en/documents/rmp/pregabalin-accord-epar-risk-management-plan_en.pdf)

## Product information

Pregabalin Accord : EPAR - Product Information

English (EN) (631.54 KB - PDF)

**First published:** 18/09/2015

**Last updated:** 27/08/2025

[View](/en/documents/product-information/pregabalin-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-821)

български (BG) (917.72 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/bg/documents/product-information/pregabalin-accord-epar-product-information_bg.pdf)

español (ES) (746.06 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/es/documents/product-information/pregabalin-accord-epar-product-information_es.pdf)

čeština (CS) (837.51 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/cs/documents/product-information/pregabalin-accord-epar-product-information_cs.pdf)

dansk (DA) (815.55 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/da/documents/product-information/pregabalin-accord-epar-product-information_da.pdf)

Deutsch (DE) (770.61 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/de/documents/product-information/pregabalin-accord-epar-product-information_de.pdf)

eesti keel (ET) (763.36 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/et/documents/product-information/pregabalin-accord-epar-product-information_et.pdf)

ελληνικά (EL) (902.15 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/el/documents/product-information/pregabalin-accord-epar-product-information_el.pdf)

français (FR) (836.16 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/fr/documents/product-information/pregabalin-accord-epar-product-information_fr.pdf)

hrvatski (HR) (829.05 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/hr/documents/product-information/pregabalin-accord-epar-product-information_hr.pdf)

íslenska (IS) (759.01 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/is/documents/product-information/pregabalin-accord-epar-product-information_is.pdf)

italiano (IT) (752.06 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/it/documents/product-information/pregabalin-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (792.16 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/lv/documents/product-information/pregabalin-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (823.12 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/lt/documents/product-information/pregabalin-accord-epar-product-information_lt.pdf)

magyar (HU) (851.01 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/hu/documents/product-information/pregabalin-accord-epar-product-information_hu.pdf)

Malti (MT) (982.53 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/mt/documents/product-information/pregabalin-accord-epar-product-information_mt.pdf)

Nederlands (NL) (760.08 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/nl/documents/product-information/pregabalin-accord-epar-product-information_nl.pdf)

norsk (NO) (812.38 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/no/documents/product-information/pregabalin-accord-epar-product-information_no.pdf)

polski (PL) (857.6 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/pl/documents/product-information/pregabalin-accord-epar-product-information_pl.pdf)

português (PT) (859.23 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/pt/documents/product-information/pregabalin-accord-epar-product-information_pt.pdf)

română (RO) (850.59 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/ro/documents/product-information/pregabalin-accord-epar-product-information_ro.pdf)

slovenčina (SK) (881.95 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/sk/documents/product-information/pregabalin-accord-epar-product-information_sk.pdf)

slovenščina (SL) (821.16 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/sl/documents/product-information/pregabalin-accord-epar-product-information_sl.pdf)

Suomi (FI) (775.33 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/fi/documents/product-information/pregabalin-accord-epar-product-information_fi.pdf)

svenska (SV) (820.03 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

27/08/2025

[View](/sv/documents/product-information/pregabalin-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000238644 27/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pregabalin Accord : EPAR - All Authorised presentations

English (EN) (39.16 KB - PDF)

**First published:** 18/09/2015

**Last updated:** 22/02/2016

[View](/en/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-66)

български (BG) (58.32 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/bg/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (41.05 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/es/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.35 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/cs/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (39.67 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/da/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (38.7 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/de/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.84 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/et/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (126.54 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/el/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (43.91 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/fr/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (52.77 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/hr/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (41.75 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/is/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (41.37 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/it/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.5 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/lv/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.23 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/lt/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (63.11 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/hu/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (57.2 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/mt/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (40.09 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/nl/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (45.86 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/no/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.19 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/pl/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (43.02 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/pt/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (60.7 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/ro/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.67 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/sk/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_sk.pdf)

Suomi (FI) (43.54 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/fi/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (39.3 KB - PDF)

**First published:**

18/09/2015

**Last updated:**

22/02/2016

[View](/sv/documents/all-authorised-presentations/pregabalin-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pregabalin Accord Active substance pregabalin International non-proprietary name (INN) or common name pregabalin Therapeutic area (MeSH)

- Anxiety Disorders
- Epilepsy

Anatomical therapeutic chemical (ATC) code N03AX16

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Epilepsy

- Pregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Generalised Anxiety Disorder

- Pregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

## Authorisation details

EMA product number EMEA/H/C/004024

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 25/06/2015 Marketing authorisation issued 28/08/2015 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pregabalin Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (155.8 KB - PDF)

**First published:** 30/08/2024

**Last updated:** 27/01/2025

[View](/en/documents/procedural-steps-after/pregabalin-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Pregabalin Accord : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (200.58 KB - PDF)

**First published:** 22/02/2016

**Last updated:** 29/08/2024

[View](/en/documents/procedural-steps-after/pregabalin-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Pregabalin Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/282380/2015

English (EN) (451.51 KB - PDF)

**First published:** 18/09/2015

**Last updated:** 18/09/2015

[View](/en/documents/assessment-report/pregabalin-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pregabalin Accord

Adopted

Reference Number: EMA/CHMP/357351/2015

English (EN) (68.01 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 26/06/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pregabalin-accord_en.pdf)

#### News on Pregabalin Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2015) 26/06/2015

#### More information on Pregabalin Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/08/2025

## Share this page

[Back to top](#main-content)